Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.05

-0.6%

Dec 9 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (60)	3/16/1999 1:35:00 PM
From: Biomaven	Read Replies (1) of 52153

GLIA isn't really a "high-risk" stock anymore - it's actually more of a "bounce" type stock. As a valuation exercise, it would be very instructive to split it into two companies - the adhesion stuff and everything else - and value them separately. SIBI is a tough valuation exercise, and it's hard to know where to start. Have to do it program by program I guess, and throw in something for their patent suit. BTRN is also hard - how do you value their long term transplant stuff? Fortunately their cash and MEDI collaboration are enough to justify their stock price, so maybe you don't really have to. Let's stick with these and NPSP for now. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next